<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001991</url>
  </required_header>
  <id_info>
    <org_study_id>107A</org_study_id>
    <secondary_id>566-501</secondary_id>
    <nct_id>NCT00001991</nct_id>
  </id_info>
  <brief_title>A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia</brief_title>
  <official_title>A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To facilitate provision of atovaquone (566C80) to patients who have mild to moderate&#xD;
      Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim /&#xD;
      sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Clinical diagnosis of acute mild to moderate Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Dose-limiting intolerance to TMP / SMX or inadequate response to TMP / SMX.&#xD;
&#xD;
          -  Willingness and ability to give informed consent. The clinical condition of the&#xD;
             patient and appropriate physiologic criteria should be used in evaluating patients for&#xD;
             therapy with 566C80. Patients who are rapidly progressing in disease severity or have&#xD;
             severe disease as evidenced by sustained tachypnea (e.g., sustained respiratory rate &gt;&#xD;
             30 breaths/minute), rapid deterioration in (A-a)DO2 and chest radiograph may not be&#xD;
             appropriate candidates for oral therapy, including 566C80. Therapy with parenteral&#xD;
             pentamidine should be undertaken in these cases. Treatment with IV trimetrexate or&#xD;
             primaquine / clindamycin should be considered for these patients unless the patient is&#xD;
             known to have dose-limiting intolerance to these agents. Patients with severe PCP who&#xD;
             are intolerant and/or unresponsive to therapy with TMP / SMX and parenteral&#xD;
             pentamidine may enroll in the 566C80 open-label compassionate plea protocol.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients with the following prior conditions are excluded: History of serious or&#xD;
        dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable&#xD;
        to the drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Day</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>atovaquone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

